ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI) (ThinkingFit)

April 25, 2014 updated by: Dr Thomas Dannhauser

Piloting a Complex Intervention Involving Physical Exercise, Cognitive Training and Socialising to Delay the Onset of Dementia in Mild Cognitive Impairment

Dementia is serious problem and around 700 000 people are affected in the UK alone. Currently there is no cure however early diagnosis and effective treatment offers hope for reducing the impact. Dementia sufferers require care due to physical disability, cognitive deficits, social isolation and emotional symptoms (depression). Delaying the onset of dementia will improve quality of life for patients and reduce the cost of residential care (£42 000 per person per year).

People with mild cognitive impairment (MCI) are at high risk of developing dementia. They have impaired cognitive abilities, such as memory, but still manage their everyday activities. Studies show that 8 out of 10 people with MCI will have developed dementia 6 years after diagnosis.

Regular physical activities and performing a variety of cognitive activities reduce the risk of dementia and improves abilities and quality of life in healthy people. Therefore a combination of these activities may reduce the risk of developing dementia in MCI. The investigators want to see if they can develop a program which combines these activities in a fun and social way that gets people active and keeps them active. The aims are to improve fitness, cognition and quality of life. The investigators plan to use computers and the internet to help with the activities and to make them available to people who are isolated. Physical activity will involve walking from home, cognitive activities will be computer based games and puzzles and socialising will involve regular varied group-based activities. Participants (128) will be recruited from the UCL Derwent Memory Clinic and will complete a 26 week program. They will then be followed up yearly to monitor their progress. The main outcome of the study is engagement in the activities. The investigators will also measure fitness, cognition, quality of life and conversion to dementia.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

128

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Essex
      • Harlow, Essex, United Kingdom, cm20 1qx
        • North Essex Partnership Foundation NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria for patients with MCI

  1. Patients fulfilling criteria for AMCI [Petersen et al. 2001b]:

    i. Memory impairment for age and education ii. No impairment in other cognitive domains iii. Normal social activities iv. Patient is not demented

  2. For the other subtypes of MCI, cognitive impairment in one or more nonmemory domain
  3. Sedentary lifestyle with no regular participation in physical exercise defined as two or three times a week for at least 20 minutes duration, or participation in active sport more than once a week, in the previous six months.
  4. Willing and able to give informed consent.
  5. Availability and access to safe exercise environments, such as paths or roads with sidewalks for walking or cycling.
  6. At low risk from serious adverse effects from increased physical activity as indicated by performance on the revised Physical activity readiness questionnaire (PARQ).

Exclusion Criteria:

Exclusion criteria for patients with MCI

  1. Type 1 (insulin dependent) diabetes mellitus.
  2. Blood pressure of 160/100 mmHg or more.
  3. Body weight more than 140% of ideal body weight.
  4. Musculoskeletal or other medical problems preventing safe participation in regular moderate intensity exercise (65-77% of predicted maximum heart rate). This will include a resting tachycardia (heart rate above 100 bpm) and history of myocardial infarction or unstable angina within the last month.

Participants with modifiable exclusion criteria will be reconsidered after successful management. Patients will be referred for medical treatment prior to commencing exercise if indicated by the PARQ and the intervention will be guided by the PARmedX.

Participants taking medications affecting heart rate will need to be on a stable dosing regime for 3 months prior to commencing in order to control for potential spurious results on fitness measures caused by these treatments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ThinkingFit
Combined physical, cognitive and social stimulation activties.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activity Compliance
Time Frame: Compliance with programmed activities will be assessed at the end of participation which is expected to be at 24 weeks
Number of participants to have completed 50% or more of the programmed activity sessions during the intervention period.
Compliance with programmed activities will be assessed at the end of participation which is expected to be at 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular fitness measure
Time Frame: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.
Cardiovascular fitness will be measured with a modified Siconolfi Step Test.
This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.
Cognitive measures
Time Frame: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.

Participants will complete the following cognitive measures:

  • Visual and auditory divided attention task
  • Verbal episodic encoding and recognition task
  • Halstead Trail Making test (TMT)
  • Verbal fluency
  • Working memory tests: digit span forwards/ backwards
This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.
Measures of quality of life and everyday activities
Time Frame: This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.
Quality of life will be measured on the World Health Organization Quality of Life (WHOQOL) - BREF and change in every day activities on the Alzheimer's Disease Cooperative Study MCI Activities of Daily Living Scale (ADCS-MCI-ADL)
This will be measured at the start, after the control period (12 weeks) and after completion of the activity interventions at around 24 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Martin Cleverley, North Essex Partnership Foundation NHS Trust
  • Study Director: Thomas M Dannhauser, PhD, University College London, North Essex Partnership NHS Foundation Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

May 17, 2012

First Submitted That Met QC Criteria

May 20, 2012

First Posted (Estimate)

May 23, 2012

Study Record Updates

Last Update Posted (Estimate)

April 28, 2014

Last Update Submitted That Met QC Criteria

April 25, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • ThinkingFit 1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on ThinkingFit programme

3
Subscribe